Claims
- 1. A method for identifying a compound that modulates angiogenesis, the method comprising the steps of:
(i) contacting the compound with a ILKAP polypeptide, the polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:2; and (ii) determining the functional effect of the compound upon the ILKAP polypeptide.
- 2. The method of claim 1, wherein the functional effect is determined in vitro.
- 3. The method of claim 2, wherein the functional effect is a physical effect.
- 4. The method of claim 2, wherein the functional effect is determined by measuring ligand binding to the polypeptide.
- 5. The method of claim 2, wherein the functional effect is a chemical effect.
- 6. The method of claim 5, wherein the functional effect is determined by measuring phosphatase activity of the polypeptide.
- 7. The method of claim 1, wherein the polypeptide is expressed in a eukaryotic host cell.
- 8. The method of claim 7, wherein the functional effect is a physical effect.
- 9. The method of claim 8, wherein the functional effect is determined by measuring ligand binding to the polypeptide.
- 10. The method of claim 1, wherein the functional effect is a chemical or phenotypic effect.
- 11. The method of claim 11, wherein the polypeptide is expressed in a eukaryotic host cell.
- 12. The method of claim 11, wherein the host cell is an endothelial cell.
- 13. The method of claim 12, wherein the functional effect is determined by measuring avb3 expression, haptotaxis, or phosphatase activity.
- 14. The method of claim 1, wherein modulation is inhibition of angiogenesis.
- 15. The method of claim 1, wherein the polypeptide is recombinant.
- 16. The method of claim 1, wherein the polypeptide comprises a sequence of SEQ ID NO:2.
- 17. The method of claim 1, wherein the compound is an antibody.
- 18. The method of claim 1, wherein the compound is an antisense molecule.
- 19. The method of claim 1, wherein the compound is a small organic molecule.
- 20. A method of modulating angiogenesis in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified using the method of claim 1.
- 21. The method of claim 20, wherein the subject is a human.
- 22. The method of claim 20, wherein the compound is an antibody.
- 23. The method of claim 20, wherein the compound is an antisense molecule.
- 24. The method of claim 20, wherein the compound is a small organic molecule.
- 25. The method of claim 20, wherein the compound inhibits angiogenesis.
- 26. A method of modulating angiogenesis in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a ILKAP polypeptide, the polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:2.
- 27. A method of modulating angiogenesis in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a nucleic acid encoding a ILKAP polypeptide, wherein the nucleic acid hybridizes under stringent conditions to a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:2.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Ser. No. 60/284,760, filed Apr. 18, 2001, herein incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60284760 |
Apr 2001 |
US |